https://www.selleckchem.com/products/gsk046.html
Since 2016, bevacizumab has been widely used to treat metastatic colorectal cancer (mCRC) in Indonesia. Nevertheless, the high cost of bevacizumab has raised the question of whether the therapy is considered cost-effective and should be included in the national health insurance system. This study aimed to assess the cost-effectiveness of bevacizumab plus chemotherapy versus chemotherapy alone for the treatment of mCRC patients. A Markov model was applied using the perspective of the Indonesian healthcare system to assess cost-effectivene
Like
Comment
Share
